Project 2: Immunogenetics of Graft-versus-Host Disease (GVHD)The long-term goals of Project 2 are to improve the outcome of unrelated donor (URD) hematopoietic celltransplantation (HCT) for the treatment of hematopoietic malignancies and other blood disorders andbroaden the availability of mismatched URD HCT through a better understanding of the immunogeneticbasis of GVHD. We propose to re-define the transplantation barrier by introducing a novel DMAmicroarraytechnique to determine the physical linkage of HLA genes in unrelated donors and recipients. Project 2 willperform HLA haplotyping of donors and recipients to address the following aims: define the probability ofidentifying HLA allele-matched, haplotype-matched unrelated donors (Specific Aim 1); determine the extentto which matching for donor haplotypes can.reduce severe acute GVHD and improve survival after unrelateddonor HCT (Specific Aim 2), and define locus- and haplotype-specific risks in unrelated HCT (Specific Aim3). The risks conferred by single HLA-A, B, C, DRB1 or DQB1 mismatches will be determined in patientstransplanted from donors matched for one haplotype. Single locus mismatches that are not associated withincreased GVHD or lower survival may permit donor selection criteria to be relaxed and thereby enable morepatients to benefit from transplantation. Among HLA allele-matched, haplotype-matched transplants, the riskof GVHD associated with the presence or absence of ancestral HLA haplotypes will be defined. Identificationof GVHD-risk haplotypes will provide clinicians with a proxy for GVHD risk and will permit a focused strategyfor laboratory-based GVHD mapping studies. The implications of this work to the overall theme of the AdultLeukemia Center Program Project are three-fold: 1) improve the safety of unrelated HCT by understandingthe genetic basis of GVHD for donor selection; 2) increase the availability of unrelated HCT by broadeningthe use of mismatched donors; and 3) increase the efficacy of unrelated HCT by understanding the geneticbasis of graft-versus-leukemia.
The aims outlined in this project will provide new information as to theinfluence of the MHC region in transplantation that will enable us to re-define the optimal alternative donor.Relevance to Public Health: We have developed a novel way to select unrelated donors for hematopoieticcell transplantation. In this project, we will test the effectiveness of this new selection technique in reducingthe incidence and severity of graft-versus-host disease and other transplant complications, and in increasingthe odds of finding an appropriate donor for patients in need.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA018029-32
Application #
7226427
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (O5))
Project Start
2006-12-01
Project End
2011-11-30
Budget Start
2006-12-01
Budget End
2008-02-29
Support Year
32
Fiscal Year
2007
Total Cost
$306,907
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1845 publications